Peritoneal Metastases from Malignant Mesothelioma.

Diffuse malignant peritoneal mesothelioma (MPM) is a rare cancer that is ultimately fatal in almost all afflicted individuals. Morbidity and mortality from MPM is due to its propensity to progress locoregionally within the abdominal cavity. Patients with MPM most commonly present with nonspecific abdominal symptoms that usually lead to diagnosis when the condition is relatively advanced. MPM is considered a chemotherapy-resistant malignancy.

• Publication year

  2018

• Venue

  Surgical Oncology Clinics of North America

• Publication date

  2018-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.soc.2018.02.010PMID 29935688
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.

  2018cited by this paper
• Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy

  2017cited by this paper
• Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

  2017cited by this paper
• Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.

  2017cited by this paper
• Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.

  2016cited by this paper
• Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.

  2016cited by this paper
• Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma

  2016cited by this paper
• The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma

  2016cited by this paper
• Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis

  2015cited by this paper
• Abstract 4803: BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma

  2015cited by this paper
• Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.

  2014cited by this paper
• Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients

  2014cited by this paper
• MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma

  2014cited by this paper
• Current Trends in the Management of Malignant Peritoneal Mesothelioma

  2014cited by this paper
• The Role of Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

  2013cited by this paper
• Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).

  2013cited by this paper
• Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy

  2013cited by this paper
• Malignant Peritoneal Mesothelioma: Prognostic Factors and Oncologic Outcome Analysis

  2013cited by this paper
• Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma.

  2013cited by this paper
• A Novel Nomogram for Peritoneal Mesothelioma Predicts Survival

  2013cited by this paper
• Combined Diffusion-Weighted and Gadolinium-Enhanced MRI Can Accurately Predict the Peritoneal Cancer Index Preoperatively in Patients Being Considered for Cytoreductive Surgical Procedures

  2012cited by this paper
• A novel tumor‐node‐metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi‐institutional database *

  2011cited by this paper
• Malignant peritoneal mesothelioma: a multicenter study on 81 cases.

  2010cited by this paper
• Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005

  2009cited by this paper
• Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through 2005

  2009cited by this paper
• Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.

  2009cited by this paper
• Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.

  2008cited by this paper
• Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.

  2007cited by this paper
• Morbidity and Mortality Assessment of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma—A Prospective Study of 70 Consecutive Cases

  2007cited by this paper
• Epidemiology of peritoneal mesothelioma: a review.

  2007cited by this paper
• h-Caldesmon, Calretinin, Estrogen Receptor, and Ber-EP4: A Useful Combination of Immunohistochemical Markers for Differentiating Epithelioid Peritoneal Mesothelioma From Serous Papillary Carcinoma of the Ovary

  2007cited by this paper
• Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.

  2005cited by this paper
• Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience.

  2002cited by this paper
• Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.

  1996cited by this paper
• Malignant mesothelioma: attributable risk of asbestos exposure.

  1994cited by this paper
• Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985.

  1988cited by this paper
• Malignant mesothelioma following radiation exposure.

  1983cited by this paper
• Peritoneal mesothelioma: natural history and response to chemotherapy.

  1983cited by this paper
• Latency of asbestos disease among insulation workers in the United States and Canada

  1980cited by this paper
• Multimodality therapy for malignant mesothelioma based on a study of natural history.

  1980cited by this paper
• Peritoneal mesothelioma.

  1972cited by this paper
• RELATION BETWEEN EXPOSURE TO ASBESTOS AND MESOTHELIOMA.

  1965cited by this paper
• Malignant peritoneal mesotheliomas. A clinicopathological analysis of 12 fatal cases

  1960cited by this paper
• A malignant tumour arising from the endothelium of the peritoneum, and producing a mucoid ascitic fluid

  year unknowncited by this paper

• Comparison of the Efficacy of First-Line Pemetrexed-Platinum and Gemcitabine-Platinum Regimens in Malignant Peritoneal Mesothelioma

  2025cites this paper
• Clinical Significance of Tumor-Infiltrating Lymphocytes in Malignant Peritoneal Mesothelioma: A Single-Center Study of 143 Cases

  2025cites this paper
• Malignant peritoneal mesothelioma with liver metastasis: A case report and literature review.

  2024cites this paper
• Potential treatment approaches for malignant peritoneal mesothelioma: in vivo and in vitro experimental study of natural killer cell immunotherapy

  2024cites this paper
• Drug sensitivity tumor cell clusters in malignant peritoneal mesothelioma

  2024cites this paper
• Case report: ATM A1159T mutation in malignant peritoneal mesothelioma may be associated with tumor recurrence

  2024cites this paper
• Establishment of a Bayesian network model to predict the survival of malignant peritoneal mesothelioma patients after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy

  2023cites this paper
• Diffuse malignant peritoneal mesothelioma presenting as small bowel obstruction

  2023cites this paper
• Zimberelimab plus chemotherapy as the first-line treatment of malignant peritoneal mesothelioma: A case report and review of literature

  2023cites this paper
• A 51-Year-Old Woman with Advanced Peritoneal Mesothelioma and Stage 3b Chronic Kidney Disease Treated with Cytoreductive Surgery and Bidirectional Intraperitoneal Cisplatin and Ifosfamide Chemotherapy: A Case Report

  2023cites this paper
• Methylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma

  2023cites this paper
• Key factors for successful cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat diffuse malignant peritoneal mesothelioma: results from specialized peritoneal cancer center in China

  2022cites this paper
• Desmoid-type fibromatosis in the setting of malignant peritoneal mesothelioma: a case report of two rare diseases

  2022cites this paper
• Malignant mesothelioma of the peritoneum mimicking primary peritonitis carcinomatosis

  2022cites this paper
• Malignant peritoneal mesothelioma.

  2022cites this paper
• A Rare Case of Malignant Peritoneum Mesothelioma Diagnosed with Surgery for a Femoral Hernia

  2021cites this paper
• Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Malign Peritoneal Mesothelioma: Clinical Aspects and Therapeutic Perspectives

  2021cites this paper
• Malignant peritoneal mesothelioma literature review: past, present, and future

  2021cites this paper
• Peritoneal mesothelioma

  2020influential citation
• Manejo del mesotelioma peritoneal maligno con citorreducción quirúrgica más quimioterapia hipertérmica intraperitoneal en el Instituto Nacional de Cancerología, Colombia: reporte de un caso y revisión bibliográfica

  2019cites this paper